This was later followed by the application of trastuzumab in the adjuvant setting for high-risk, node-positive HER2+ breast cancer patients based on the results of 5 landmark trials (NSABP B-31, HERA, NCCTG N9831, BCIRG-006, and FinHER)4–8. This evidence concerns the gene ERBB2 and breast carcinoma.